Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy

NCT02540330 is registered in ClinicalTrials.gov with Atossa Therapeutics, Inc. as lead sponsor.

NCT NCT02540330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02540330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy
Lead sponsor
Atossa Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2016
Completion date
August 13, 2020
Enrollment
3 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

female breast carcinoma, female ductal carcinoma in situ